Skip to main content

Table 4 Bone formation and resorption markers

From: Choline-stabilized orthosilicic acid supplementation as an adjunct to Calcium/Vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial

 

Placebo

ch-OSA

    

3 mg Si

6 mg Si

12 mg Si

 

Baseline

6 months

12 months

Baseline

6 months

12 months

Baseline

6 months

12 months

Baseline

6 months

12 months

serum OC (ng/mL)

9.74 ± 3.16

9.11 ± 3.73a

7.86 ± 2.26a

10.17 ± 3.91

9.11 ± 3.02a

8.33 ± 2.63a

10.65 ± 3.32

9.74 ± 3.05a

9.08 ± 2.56a

10.16 ± 3.67

9.43 ± 3.02a

8.79 ± 2.82a

serum BAP (U/L)

21.65 ± 6.30

18.91 ± 5.56

18.61 ± 5.56

20.43 ± 7.24

19.61 ± 6.66

18.97 ± 5.98

21.85 ± 6.31

20.59 ± 6.39

20.16 ± 6.01

21.58 ± 7.36

20.19 ± 5.62

19.75 ± 5.96

serum PINP (μg/L)

47.20 ± 13.45

40.83 ± 14.05a

36.49 ± 12.04a

46.28 ± 21.46

40.27 ± 20.18a

35.63 ± 12.34a

44.78 ± 16.07

38.60 ± 13.35a

42.04 ± 12.77a,1,2

48.77 ± 15.09

42.87 ± 11.89a,2

43.73 ± 12.11a,1,2

serum DPD (/Cr)

5.57 ± 3.12

4.77 ± 1.12

4.74 ± 1.28

5.22 ± 1.50

5.17 ± 2.04

4.83 ± 1.62

5.74 ± 1.45

5.81 ± 1.68

5.49 ± 1.70

5.92 ± 1.57

5.36 ± 1.91

6.22 ± 2.62

serum CTX-I (μg/mmol Cr)

359.01 ± 129.89

271.15 ± 124.21

284.66 ± 134.09

331.88 ± 155.87

245.03 ± 107.82

220.71 ± 98.08

349.10 ± 126.71

294.21 ± 137.802

319.38 ± 160.782

360.43 ± 139.00

310.95 ± 122.052

320.99 ± 113.632

  1. Bone formation and resorption markers at baseline (mean ± SD) and after 6 and 12 months supplementation with placebo (Ca/vit D) and three different ch-OSA doses (Si + Ca/vit D; Si: 3, 6, 12 mg/day). a: p < 0.05 (MANCOVA, vs. baseline), 1: p < 0.05 (MANCOVA, vs. placebo) and 2: p < 0.05 (MANCOVA, vs. 3 mg Si).
  2. OC: osteocalcin, BAP: bone specific alkaline phosphatase, PINP: procollagen type I N-terminal propeptide, DPD: deoxypyridinoline, CTX-I: C-terminal collagen type I.